Profiles

Keywords
Last Name
Institution

Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.

Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, Kuzel TM. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma. 2009 Dec; 50(12):1969-76.

View in: PubMed

collapse authors with profiles